No Data
No Data
Sanofi Hits 23-week Low
Sanofi's Multiple Sclerosis Therapy Tolebrutinib Gets US FDA's Breakthrough Designation
Gilead Sciences Names Dietmar Berger as Chief Medical Officer
Sanofi's Combo Vaccines Gain FDA Fast Track Designation
Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com
Express News | Sanofi's Dual Influenza-COVID-19 Vaccines Receive FDA Fast Track Designation For Individuals 50 Years Of Age And Older